Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Merus	AnaptysBio	Gossamer Bio	OrganiGram	Calliditas Therapeutics AB (publ)
Symbol	NASDAQ:MRUS	NASDAQ:ANAB	NASDAQ:GOSS	NASDAQ:OGI	NASDAQ:CALT
Price Information
Current Price	$22.52	$21.72	$8.49	$2.52	$26.88
52 Week Range	Buy	Hold	Buy	Hold	Buy
MarketRank™
Overall Score	1.6	1.5	1.7	1.6	1.4
Analysis Score	2.4	3.1	3.5	4.1	3.5
Community Score	2.5	2.8	2.5	3.0	2.8
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	2.5	1.7	1.7	0.0	0.0
Earnings & Valuation Score	0.6	0.0	0.6	0.6	0.6
Analyst Ratings
Consensus Recommendation	Buy	Hold	Buy	Hold	Buy
Consensus Price Target	$27.80	$30.29	$23.00	$4.41	$40.80
% Upside from Price Target	23.45% upside	39.44% upside	170.91% upside	75.05% upside	51.79% upside
Trade Information
Market Cap	$858.62 million	$594.39 million	$641.23 million	$585.32 million	$671.22 million
Beta	0.83	0.15	1.34	0.3	N/A
Average Volume	175,877	534,660	671,687	24,025,842	32,682
Sales & Book Value
Annual Revenue	$31.13 million	$8 million	N/A	$64.61 million	$19.56 million
Price / Sales	27.58	74.30	N/A	9.06	34.32
Cashflow	N/A	N/A	N/A	$0.02 per share	N/A
Price / Cash	N/A	N/A	N/A	101.50	N/A
Book Value	$5.61 per share	$14.93 per share	$5.34 per share	$1.04 per share	N/A
Price / Book	4.01	1.45	N/A	2.42	∞
Profitability
Net Income	$-55,150,000.00	$-97,340,000.00	$-180,310,000.00	$-101,290,000.00	$-3,450,000.00
EPS	($2.33)	($3.60)	($3.29)	($0.08)	($0.19)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-295.98%	N/A	N/A	-207.26%	N/A
Return on Equity (ROE)	-78.70%	-19.09%	-64.34%	-10.00%	-26.80%
Return on Assets (ROA)	-36.12%	-17.94%	-46.52%	-7.14%	-25.38%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	0.46%	0.17%	N/A
Current Ratio	4.43%	14.13%	17.36%	2.66%	23.46%
Quick Ratio	4.43%	14.13%	17.36%	3.39%	23.46%
Ownership Information
Institutional Ownership Percentage	62.57%	N/A	71.96%	10.84%	11.85%
Insider Ownership Percentage	7.40%	13.00%	23.30%	N/A	N/A
Miscellaneous
Employees	93	94	195	516	34
Shares Outstanding	38.13 million	27.37 million	75.53 million	232.27 million	24.97 million
Next Earnings Date	5/10/2021 (Estimated)	5/5/2021 (Estimated)	5/11/2021 (Estimated)	7/20/2021 (Estimated)	5/13/2021 (Estimated)
Optionable	Not Optionable	Optionable	Not Optionable	Not Optionable	Not Optionable

Source	Headline
	Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Given Average Rating of "Buy" by Analysts americanbankingnews.com - April 17 at 6:40 AM
	Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Strong Trading Volume americanbankingnews.com - April 12 at 11:32 AM
	Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Unusually-High Trading Volume americanbankingnews.com - April 5 at 12:06 PM
	Short Interest in Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Expands By 211.7% americanbankingnews.com - March 28 at 5:12 AM
	Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $29.61 americanbankingnews.com - March 24 at 1:54 PM
	Calliditas Therapeutics Files US Application For Nefecon In Kidney Disease finance.yahoo.com - March 15 at 2:40 PM
	Agenda for Calliditas virtual R&D Day on January 20, 2021 prnewswire.com - January 15 at 4:35 AM

Date	Company	Brokerage	Action
4/14/2021	Merus	William Blair	Initiated Coverage
3/23/2021	Merus	HC Wainwright	Boost Price Target
3/23/2021	Merus	Royal Bank of Canada	Boost Price Target
3/22/2021	Merus	SVB Leerink	Initiated Coverage
1/19/2021	Merus	Roth Capital	Boost Price Target
5/18/2020	Merus	Guggenheim	Lower Price Target
4/5/2019	Merus	Wedbush	Lower Price Target
3/27/2019	Merus	Berenberg Bank	Initiated Coverage
3/21/2019	Merus	Citigroup	Lower Price Target
3/22/2021	AnaptysBio	Truist Securities	Upgrade
3/8/2021	AnaptysBio	JPMorgan Chase & Co.	Downgrade
5/7/2020	AnaptysBio	Credit Suisse Group	Boost Price Target
5/6/2020	AnaptysBio	Stifel Nicolaus	Reiterated Rating
3/3/2020	AnaptysBio	SunTrust Banks	Lower Price Target
11/8/2019	AnaptysBio	Jefferies Financial Group	Downgrade
8/20/2019	AnaptysBio	Cantor Fitzgerald	Set Price Target
10/16/2020	Gossamer Bio	Barclays	Lower Price Target
10/13/2020	Gossamer Bio	Piper Sandler	Lower Price Target
12/3/2019	Gossamer Bio	Bank of America	Initiated Coverage
8/12/2019	Gossamer Bio	Evercore ISI	Set Price Target
4/14/2021	OrganiGram	Raymond James	Lower Price Target
4/14/2021	OrganiGram	Canaccord Genuity	Boost Price Target
4/14/2021	OrganiGram	CIBC	Downgrade
4/13/2021	OrganiGram	Alliance Global Partners	Lower Price Target
4/8/2021	OrganiGram	BMO Capital Markets	Upgrade
8/18/2020	Calliditas Therapeutics AB (publ)	Ci Capital	Reiterated Rating

(Data available from 4/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources